Ripple Therapeutics Appoints Jonathan Talamo, M.D., to Board of Directors ACCESSWIRE 04 May 2021, 22:05 GMT+10 TORONTO, ON / ACCESSWIRE / May 4, 2021 / Ripple Therapeutics Corporation ('Ripple') a clinical stage, ophthalmology-focused developer of novel pharmaceuticals, is pleased to announce the appointment of Jonathan Talamo, M.D., to the Board of Directors. Dr. Talamo is internationally known as an ophthalmologist, innovator and consultant to industry with more than 25 years of experience in healthcare. Dr. Talamo is the former Chief Medical Officer and Worldwide VP of Clinical and Medical Affairs at Johnson and Johnson Vision. Prior to that, he served as the Chief Medical Officer at Ocular Therapeutix, an ophthalmic drug delivery company, where he oversaw clinical development programs in multiple therapeutic areas, including post-cataract surgery inflammation, dry eye, allergy, glaucoma and retinal vascular diseases.